45 results about "Blood fluidity" patented technology

Black currant anthocyanin-containing compositions for foods comprising 1 to 25% by weight of black currant anthocyanin on the basis of solid matters; a process for producing a black currant anthocyanin-containing composition for foods characterized by purifying and concentrating black currant juice employed as a starting material by using a charged reverse osmosis membrane; functional foods and drinks characterized by containing the above compositions for foods; and the above-described compositions for foods and the above-described functional foods and drinks having an effect of improving visual function, a function of improving blood fluidity, and / or a function of lowering blood pressure. The conventional black currant anthocyanin compositions have a low black currant anthocyanin content, strong acidity and poor stability, which makes them unsuitable as additives for foods and drinks. However, the production process according to the present invention makes it possible to provide black currant anthocyanin-containing compositions for foods which have a high black currant anthocyanin content, an adequate acidity, and a high stability and can be added to foods and drinks. Moreover, functional foods and drinks containing these compositions, which have an effect of improving visual function, a function of improving blood fluidity, or a function of lowering blood pressure, can be provided.

A blood fluidity-improving agent, a blood circulation promoter or a cerebrovascular disease-improving agent, containing as an active ingredient thereof one or more ingredients selected from the group consisting of chlorogenic acids, caffeic acids, ferulic acids and pharmaceutically acceptable salts of these acids. The present blood fluidity-improving agent, blood circulation promoter or cerebrovascular disease-improving agent is highly safe and can be orally taken over longer periods of time.

A blood fluidity improving agent, a blood flow promoting agent and a cerebrovascular disorder ameliorating agent containing, as the active ingredient, at least one member selected from among chlorogenic acids, caffeic acid, ferulaic acid and pharmaceutically acceptable salts thereof. The above-described blood fluidity improving agent, blood flow promoting agent and cerebrovascular disorder ameliorating agent are highly safe and can be taken over a long period of time.

The invention provides a melanin regeneration dropping pill, pertaining to the drugs used for curing Leucoderma, which is prepared from the raw materials of active ingredients of long pepper, fructus psoraleae, tribulus and angelica. The results of clinical use show that the invention has the following advantages of: 1) instant effect that the invention has quick results in 1-4 days; short courseof treatment that the invention can cure the disease in 1-2 courses of treatment; high cure rate that the total cure rate is 84.2 percent; difficult recurrence; 2) the functions of reducing blood viscosity, promoting blood fluidity, improving microcirculation, increasing the content of copper-protein, lowering humoral immunity, enhancing cellular immunity and accelerating the melanin regeneration; 3) safe and effective clinical use and no obvious toxic side effect; 4) low treatment cost that the invention has the advantages of low cost and easy preparation, etc., compared with similar drugs used for curing Leucoderma, which can reduce the economic burden of a patient; 5) quick release and high bioavailability.

The invention relates to a hemoconcentrator shell, which comprises a cylinder body and end covers which are hermetically connected at both ends of the cylinder body, wherein Luer cone joints are arranged on the end covers; the cylinder body comprises a main cylinder body, a connecting cylinder body of which both ends are larger than the diameter of the main cylinder body, and a cone cylinder bodywhich is connected between the main cylinder body and the connecting cylinder body, and the slenderness ratio of the cylinder body is between 6.5 and 8.5; two equidirectional and axially symmetrical tube holders are arranged on the cone cylinder body and extended to one side of the main cylinder body; liquid tube joints on the tube holders are communicated with an inner cavity of the main cylinder body; baffle plates on the inner wall of the main cylinder body are arranged at the bottom of the tube holders; internal threads on the end covers are connected with external threads of the connecting cylinder body in a mode of screwed joint; and seal rings which are arranged on the end face of the connecting cylinder body are arranged inside ring grooves of the end covers. The hemoconcentrator shell has the characteristics of convenient operation and good blood fluidity.